Legion Partners Asset Management LLC Acquires 1,463,414 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Legion Partners Asset Management LLC boosted its holdings in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Free Report) by 49.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,431,823 shares of the company's stock after acquiring an additional 1,463,414 shares during the period. Lifecore Biomedical accounts for approximately 22.0% of Legion Partners Asset Management LLC's investment portfolio, making the stock its 3rd biggest position. Legion Partners Asset Management LLC owned about 11.97% of Lifecore Biomedical worth $32,928,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Jane Street Group LLC boosted its holdings in shares of Lifecore Biomedical by 101.7% during the 3rd quarter. Jane Street Group LLC now owns 36,246 shares of the company's stock worth $179,000 after purchasing an additional 18,277 shares during the last quarter. Barclays PLC grew its holdings in Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company's stock valued at $147,000 after buying an additional 22,489 shares in the last quarter. MassMutual Private Wealth & Trust FSB purchased a new stake in Lifecore Biomedical in the 4th quarter valued at $209,000. ARS Investment Partners LLC acquired a new stake in shares of Lifecore Biomedical in the 4th quarter worth $74,000. Finally, Rhumbline Advisers raised its holdings in shares of Lifecore Biomedical by 125.9% during the 4th quarter. Rhumbline Advisers now owns 55,723 shares of the company's stock worth $414,000 after acquiring an additional 31,056 shares during the period. Institutional investors and hedge funds own 83.36% of the company's stock.

Lifecore Biomedical Trading Up 0.6%

Shares of LFCR stock traded up $0.04 on Thursday, hitting $6.71. 168,903 shares of the stock traded hands, compared to its average volume of 234,613. Lifecore Biomedical, Inc. has a twelve month low of $3.68 and a twelve month high of $7.99. The stock has a market capitalization of $248.44 million, a PE ratio of -11.98 and a beta of 0.65. The firm's 50-day moving average price is $6.46 and its two-hundred day moving average price is $6.52. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32.

Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $35.15 million during the quarter, compared to analysts' expectations of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, analysts anticipate that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Insider Buying and Selling

In other Lifecore Biomedical news, major shareholder Aron R. English sold 15,847 shares of Lifecore Biomedical stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $7.01, for a total value of $111,087.47. Following the sale, the insider now owns 1,714,070 shares in the company, valued at $12,015,630.70. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders sold 86,788 shares of company stock worth $611,009. Company insiders own 32.20% of the company's stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.